C.F.R. homeSearch C.F.R.
C.F.R.Title 21Chapter I—Food and Drug Administration, Department of Health and Human ServicesSubchapter D—Drugs for Human UsePart 312—Investigational New Drug ApplicationSubpart B—Investigational New Drug Application (Ind)

21 C.F.R. § 312.33 (2026)

Annual reports

Edition and currency
eCFR text as of Sept. 29, 2026. The text is the edition Syfert holds; for a past event, check the version in force on that date.
Other sources
CURRENTeCFR text as of Sept. 29, 2026 ACTIVE · 1 IN 5Y cited 2017–2021 3citing cases
At a glance

Courts have cited this section in 3 opinions since 2017, 1 of them in the last five years. The most litigated part is subsection (b)(1) (1 case).

Link to an amendment published at 91 FR 60003, Sept. 22, 2026.

A sponsor shall within 60 days of the anniversary date that the IND went into effect, submit a brief report of the progress of the investigation that includes:

(a) Individual study information. A brief summary of the status of each study in progress and each study completed during the previous year. The summary is required to include the following information for each study:

(1) The title of the study (with any appropriate study identifiers such as protocol number), its purpose, a brief statement identifying the patient population, and a statement as to whether the study is completed.

(2) The total number of subjects initially planned for inclusion in the study; the number entered into the study to date, tabulated by age group, gender, and race; the number whose participation in the study was completed as planned; and the number who dropped out of the study for any reason.

(3) If the study has been completed, or if interim results are known, a brief description of any available study results.

(b) Summary information. Information obtained during the previous year's clinical and nonclinical investigations, including:

(1) A narrative or tabular summary showing the most frequent and most serious adverse experiences by body system.

(2) A summary of all IND safety reports submitted during the past year.

(3) A list of subjects who died during participation in the investigation, with the cause of death for each subject.

(4) A list of subjects who dropped out during the course of the investigation in association with any adverse experience, whether or not thought to be drug related.

(5) A brief description of what, if anything, was obtained that is pertinent to an understanding of the drug's actions, including, for example, information about dose response, information from controlled trials, and information about bioavailability.

(6) A list of the preclinical studies (including animal studies) completed or in progress during the past year and a summary of the major preclinical findings.

(7) A summary of any significant manufacturing or microbiological changes made during the past year.

(c) A description of the general investigational plan for the coming year to replace that submitted 1 year earlier. The general investigational plan shall contain the information required under § 312.23(a)(3)(iv).

(d) If the investigator brochure has been revised, a description of the revision and a copy of the new brochure.

(e) A description of any significant Phase 1 protocol modifications made during the previous year and not previously reported to the IND in a protocol amendment.

(f) A brief summary of significant foreign marketing developments with the drug during the past year, such as approval of marketing in any country or withdrawal or suspension from marketing in any country.

(g) If desired by the sponsor, a log of any outstanding business with respect to the IND for which the sponsor requests or expects a reply, comment, or meeting.

[52 FR 8831, Mar. 19, 1987, as amended at 52 FR 23031, June 17, 1987; 63 FR 6862, Feb. 11, 1998; 67 FR 9585, Mar. 4, 2002]
The 3 cases that cite 21 C.F.R. § 312.33 most heavily, weighted by court and treatment. RelevanceNewestTreatment
1
GREENBrennan v. Zafgen, Inc., 853 F.3d 606 (1st Cir. 2017).
cites § 312.33 2×subsections: (b)(1)cited by 32 cases
Where it cites § 312.33
“See 21 C.F.R. § 312.33 (b)(1) (stating that developers, in their annual reports to the FDA, must disclose summary information “showing the most frequent and the most serious” adverse events observed during that year’s clinical and nonelinical drug investigations).”
The case’s holding
A complaint lacking direct evidence of scienter must rely on indirect evidence that is sufficient to raise a strong inference of fraudulent intent.
Later courts cite it for
“where a complaint is devoid of any direct-evidence allegations, the indirect-evidence allegations in the complaint will need to do more work to carry the burden of raising a 'strong inference of scienter' on their own.” · 3 citing courts
2
GREENIn re Zofran (Ondansetron) Prods. Liab. Litig., 368 F. Supp. 3d 94 (D.D.C. 2019).
cites § 312.33 2×cited by 1 case
Where it cites § 312.33
“The Annual Report, submitted to the FDA pursuant to 21 C.F.R. § 312.33 , provided the name and study number for each of the three studies, among other reproduction studies conducted on Zofran in Japan.”
3
NO FLAGLeclair v. GlaxoSmithKline LLC, No. 1:15-cv-10429 (D. Mass. June 1, 2021).
cites § 312.33 1×cited by 0 casesunknown
Where it cites § 312.33
“The Annual Report, submitted to the FDA pursuant to 21 C.F.R. § 312.33 , 13 Study No. 100423 was not included, as it was a preliminary study conducted “[t]o establish the dose levels” for the definitive Study No.”

The flag is Syfertize’s treatment of the citing case itself, not of the statute. “Where it cites” is the passage in the opinion; the holding is a summary of the whole case and may concern another point. Annotations are extracted automatically from the opinions in the Syfert caselaw corpus.

Citing cases by year
201720192021

One bar per year. Tallest: 1 case in 2017. These are opinions in the Syfert collection, which holds more of some courts’ recent opinions than their older ones, so a rise can reflect what the collection holds and not more litigation.

By court
1st Cir.1D.D.C.1D. Mass.1
By subsection
(b)(1)1 case
Brennan v. Zafgen, Inc., 853 F.3d 606 (1st Cir. 2017).“See 21 C.F.R. § 312.33 (b)(1) (stating that developers, in their annual reports to the FDA, must disclose summary information “showing the most frequent and the most serious” adverse events observed during that year’s clinical and nonelinical drug investigations).”
Enactment and amendments

Syfert holds no separate history line for this section. Where this code prints a source or history note, it appears with the text, usually at the end.

Versions

Edition shown: eCFR text as of Sept. 29, 2026. Syfert holds no earlier or later version of this section.

C.F.R. Home  |  Search C.F.R.  |  Search cases for this section  |  syfert.com